At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Mar 4, 2026 at 03:30 ET
HUTCHMED has initiated a Phase I/IIa clinical trial for HMPL-A580, its second Antibody-Targeted Therapy Conjugate (ATTC), in patients with advanced solid tumors in both China and the US. The first patient was dosed on March 4, 2026, marking a key step in the development of this first-in-class therapy targeting the PAM pathway and EGFR signaling.
- HUTCHMED initiated a Phase I/IIa trial for HMPL-A580, its second ATTC candidate, on March 4, 2026.
- The trial is ongoing in the US and China and is first-in-human, evaluating safety, pharmacokinetics, and preliminary efficacy.
- HMPL-A580 combines a novel PI3K/PIKK inhibitor payload with an anti-EGFR antibody to target EGFR-expressing solid tumors.
- Preclinical data suggest synergistic activity between PAM pathway inhibition and EGFR blockade.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access